



Franklin Templeton Investment Funds
Franklin Biotechnology Discovery Fund

Sector Equity
 30.04.2023

Fund Fact Sheet

Fund Overview

Base Currency for Fund	USD
Total Net Assets (USD)	1.79 billion
Fund Inception Date	03.04.2000
Number of Issuers	77
Benchmark	NASDAQ Biotechnology Index
Morningstar Category™	Sector Equity Biotechnology

Minimum Investment

Share Class	Initial	Subsequent
A (acc) USD	USD 1,000	USD 500
A (acc) SGD	SGD 1,000	SGD 500

Summary of Investment Objective

The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies and discovery research firms mainly located in the US.

Fund Management

Evan McCulloch, CFA: United States
 Wendy Lam, PhD: United States
 Akiva Felt: United States

Ratings - A (acc) USD

Overall Morningstar Rating™: ★★ ★


Asset Allocation

	%
Equity	96.62
Cash & Cash Equivalents	3.38

Performance

Past performance does not predict future returns.

Performance over 5 Years in Share Class Currency (%)



Performance in Share Class Currency (%)

	Cumulative					Annualised	
	1 Mth	3 Mths	YTD	1 Yr	Since Incept	3 Yrs	Since Incept
A (acc) USD	3.72	-0.59	4.38	9.63	240.29	-0.85	5.45
After Sales Charge*	-1.47	-5.56	-0.84	4.15	223.28	-2.53	5.22
Benchmark in USD	1.50	-3.98	-0.61	11.35	293.07	2.40	6.11
A (acc) SGD	3.96	0.95	3.96	5.72	230.67	-2.67	8.01
After Sales Charge*	-1.24	-4.10	-1.24	0.43	214.13	-4.31	7.66
Benchmark in SGD	1.77	-2.47	-0.99	7.43	343.06	0.53	10.07

Top Ten Holdings (% of Total)

Issuer Name	%
VERTEX PHARMACEUTICALS INC	7.12
AMGEN INC	6.51
REGENERON PHARMACEUTICALS INC	6.49
GILEAD SCIENCES INC	5.69
ASTRAZENECA PLC	4.91
BIOGEN INC	4.40
JAZZ PHARMACEUTICALS PLC	4.37
PTC THERAPEUTICS INC	4.23
INTRA-CELLULAR THERAPIES INC	3.29
ARGENX SE	3.14

Share Class Information (For a full list of available share classes, please visit www.franklintempleton.com.sg.)

Share Class	Incept Date	NAV	TER (%)	Fees	
				Max. Sales Charge (%)	Max. Annual Charge (%)
A (acc) USD	03.04.2000	USD 34.03	1.82	5.00	1.50
A (acc) SGD	25.10.2007	SGD 33.07	1.82	5.00	1.50

Additional Share Class Information

Share Class	Incept Date	Subscription Type	Dividends			Fund Identifiers	
			Frequency	Bloomberg ID	ISIN		
A (acc) USD	03.04.2000	Cash	N/A	TEMBDAI LX	LU0109394709		

Share Class	Incept Date	Subscription Type	Dividends	Fund Identifiers	
			Frequency	Bloomberg ID	ISIN
A (acc) SGD	25.10.2007	Cash/SRS	N/A	TEBTASG LX	LU0320765992

Composition of Fund

Market Capitalisation Breakdown in

USD	% of Equity
<2.0 Billion	16.40
2.0-5.0 Billion	16.11
5.0-10.0 Billion	12.15
10.0-25.0 Billion	8.90
25.0-50.0 Billion	11.17
>50.0 Billion	35.08
N/A	0.18

What Are the Key Risks?

The value of shares in the Fund and income received from it can go down as well as up and investors may not get back the full amount invested. Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments. The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate very significantly over relatively short time periods. Other significant risks include: securities lending risk, equity risk. For full details of all of the risks applicable to this Fund, please refer to the "Risk Considerations" section of the Fund in the current prospectus of Franklin Templeton Investment Funds.

Important Information

This fund has been classified as Article 8 under the Regulation on sustainability related disclosures in the financial services sector (EU) 2019/2088. These are Funds which have an ESG integration approach and, in addition, have binding environmental and/or social characteristics in their investment process.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.

In addition, a summary of investor rights is available from <https://www.franklintempleton.com.sg/summary-of-investors-rights.pdf>. The summary is available in English. The sub-funds of FTIF are notified for marketing in multiple EU Member States under the UCITS Directive. FTIF can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive. For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the Fund and will not be investing directly in the underlying assets of the Fund.

Copyright© 2023. Franklin Templeton. All Rights Reserved. Issued by Templeton Asset Management Ltd. Registration No.(UEN) 199205211E.

This document is for information only and does not constitute investment advice or a recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested. Past performance is not an indicator or a guarantee of future performance. Subscriptions may only be made on the basis of the most recent Prospectus and Product Highlights Sheet which is available at Templeton Asset Management Ltd or our authorised distributors. Potential investor should read the details of the Prospectus and Product Highlights Sheet before deciding to subscribe for or purchase the Fund. This shall not be construed as the making of any offer or invitation to anyone in any jurisdiction in which such offer is not authorised or in which the person making such offer is not qualified to do so or to anyone to whom it is unlawful to make such an offer. In particular, this Fund is not available to U.S. Persons and Canadian residents. **Investors may wish to seek advice from a financial adviser before making a commitment to invest in shares of the Fund. In the event an investor chooses not to seek advice from a financial adviser, he/she should consider whether the Fund is suitable for him/her.**

Performance: Performance details provided are in the share class currency, based on NAV-NAV and include reinvested dividends. Performances of different share classes will vary. Please refer to the Fund Manager for more information.

References to indices are made for comparative purposes only and are provided to represent the investment environment existing during the time periods shown. When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

Charges: The charges are the fees the fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by the Fund, which will impact on the overall return of the Fund. Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.

Fund Management: CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

Ratings: © Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

After Sales Charge*: Calculated based on initial sales charge of 5%; or 0% for Money Market Funds.

Top Ten Holdings: These securities do not represent all of the securities purchased, sold or recommended and readers should not assume that investment in the securities listed was or will be profitable. All portfolio holdings are subject to change.